Company ProfilePremium

Mayne Pharma Group Limited

Company Profile Analysis

Ticker: MYX.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Mayne Pharma Group Limited - Company showcase

Year Founded & Workforce

2005

470 Employees

Mayne Pharma Group Limited logo

Mayne Pharma Group Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Mayne Pharma Group Limited Overview

Mayne Pharma is a small-cap specialty pharmaceutical company. It is listed in Australia, but its economic centre of gravity is the United States, where roughly 82% of revenue is generated.

Since FY22 it has been rebuilt from a debt-laden generics and contract-manufacturing conglomerate into a branded US women's-health and dermatology franchise. It is anchored by four women's-health brands:

  • NEXTSTELLIS®, an estetrol-based oral contraceptive

  • ANNOVERA®, a one-year vaginal ring

  • IMVEXXY®, a vaginal estradiol insert

  • BIJUVA®, an estradiol/progesterone capsule

These sit alongside a margin-focused dermatology portfolio and an Australian manufacturing and export arm at Salisbury.

Its newest strategic asset is DistributeRx. Launched in March 2026, it is a direct-to-patient, cash-pay prescription channel built on its Adelaide Apothecary mail-order pharmacy, and it is now open to third-party manufacturers.

FY26 revenue was A$383.7m at a 64.7% gross margin, with underlying EBITDA of A$34.2m. The company holds A$80.0m of cash against A$43.2m of interest-bearing debt. Large contingent earn-out liabilities (A$265.5m) linked to acquired brands are the main balance-sheet overhang.


Company's own description (FY26 Annual Report, paraphrased)

The company describes itself as an ASX-listed specialty pharmaceutical company that commercialises novel branded women's-health and dermatology medicines. Its stated aim is to offer patients better, safe and more accessible medicines.

It points to:

  • A 40-year record in oral drug-delivery technologies.

  • A Salisbury (South Australia) development and manufacturing facility with expertise in complex oral and topical dose forms, including modified-release products and poorly soluble compounds.

  • A contract development and manufacturing (CDMO) service for third parties.

Independent characterisation

Mayne Pharma is best understood as a US commercial-stage, in-licensing and acquisition-led branded pharma platform. It has an Australian manufacturing tail. It does not carry out early-stage drug discovery.

Its model has three parts:

  1. Acquiring or licensing late-stage or already-approved US brands. Consideration is often heavily deferred through earn-outs and royalties.

  2. Re-launching those brands through a focused US sales force of OB/GYN and dermatology representatives, supported by medical science liaisons.

  3. Managing gross-to-net economics through channel strategy: specialty pharmacies, its own Adelaide Apothecary mail-order pharmacy, GoodRx-enabled cash prices, and now DistributeRx.

The Australian business manufactures and sells branded and generic products ex-US and provides CDMO services.

Revenue model mix

Revenue line (AUD Mn)FY2024FY2025FY2026
Sale of goods351.8364.2352.3
Services revenue35.342.426.0
Licence fee revenue0.20.40.0
Royalties revenue1.11.25.3
Total revenue388.4408.1383.7

Source: FY25 and FY26 Annual Reports, consolidated statement of profit or loss.

Mix in FY26:

  • Products: 91.8% of revenue.

  • Services: 6.8%, mainly distribution, pharmacy and contract-manufacturing related.

  • Royalties: 1.4%.

  • There is no subscription revenue.

  • Branded products were 83% of net sales in FY26, up from 79% in FY25. Generics were 17% (FY26 Annual Report).

Value-chain position

Value-chain stageMayne role
Discovery / early R&DMinimal. R&D expense is mainly post-marketing studies and lifecycle work (A$20.7m in FY26)
Late-stage development / regulatorySelective: post-approval FDA studies for ANNOVERA® and IMVEXXY®; formulation work at Salisbury
ManufacturingUS brands are largely third-party manufactured. Salisbury makes Australian and export products and CDMO volumes
CommercialisationCore competency: US field force and marketing for women's health; digital and channel-led dermatology
Distribution / dispensingIncreasingly vertical: Adelaide Apothecary (licensed US mail-order pharmacy) and DistributeRx (direct-to-patient platform)

Customers and end-markets

Ultimate prescribers: - US OB/GYNs, women's-health nurse practitioners and primary care physicians.

  • US dermatologists, with 5,042 unique prescribers using DistributeRx since its March 2026 launch.

  • Australian GPs and specialists.

Paying and purchasing customers: - US wholesalers and specialty pharmacies (more than 400 in the dermatology channel network).

  • PBMs and payers, through rebates.

  • Patients paying cash through Adelaide Apothecary and DistributeRx.

  • Australian pharmacy wholesalers, with PBS reimbursement.

  • Export distributors, for example KADIAN® in Canada.

  • CDMO clients.

End-markets: - US contraception

  • US menopause and hormone therapy

  • US medical dermatology (acne, rosacea, psoriasis)

  • Australian prescription pharmaceuticals, including pain (opioids) and urology

  • Contract manufacturing

Strategy

Stated strategic priorities (FY26 Annual Report, paraphrased)

PriorityStated activities
Deliver the profit potential of the current Women's Health portfolioSharpen sales execution and targeted marketing for operating leverage; protect long-term asset value through IP management and Key Opinion Leader (KOL) education; evaluate complementary assets
Differentiate the channel to become the preferred solution for patients, prescribers and partnersMake channel processes easy to use; pursue capital-efficient, accretive dermatology business development; broaden the product range on the platform
Drive international profit through new revenue streams and modernisationUse Salisbury capacity; targeted maintenance capex only; expand KAPANOL®/KADIAN® ex-Australia

FY27 outlook themes (FY26 results)

Women's Health: accelerate growth through a focused sales force, refreshed marketing and better prescriber access. The tailwind is the removal of the HRT boxed warning, especially for BIJUVA®.

Dermatology / DistributeRx: scale the platform. Management expects some loss of insurance coverage for TWYNEO® and generic entry against RHOFADE®.

International: build on the NEXTSTELLIS® PBS listing; grow exports and CDMO revenue from the Salisbury investment.

Corporate: evaluate capital-efficient, synergistic acquisitions alongside disciplined capital management. Earlier (Feb 2026) the CEO also listed share repurchases as a capital-allocation option under evaluation.

Strategic initiatives register (last 24 months)

InitiativeDateDescriptionTarget / status
Women's Health marketing refreshFY25New marketing materials across all brandsCompleted
TWYNEO® / EPSOLAY® acquisition and launchApr 2025; launched 1H FY26Two FDA-approved topical brands for US$16mLaunched; coverage risk in FY27
Salisbury modernisationFY23–Dec 2025A$18m upgrade (encapsulation, blister, bottling lines)Completed; DIFOT 97.4%
NEXTSTELLIS® PBS listingEffective 1 Oct 2025Reimbursed access in AustraliaDemand cycles +127% in FY26
Retention programDec 2025Cash and RSU retention awards; quarterly STIRSUs vest Sep 2026
Board and management renewalJan–Aug 2026Board cut to 5; new Chair, CEO and CFO; US commercial and shareholder-investor directors addedCompleted
Women's Health field force expansion2H FY26National realignment; menopause and contraception specialists in metro marketsOngoing; drove the EBITDA dip
DistributeRx launchMar 2026Direct-to-patient cash-pay platform, plus manufacturer services as a B2B revenue stream62k TRx in first full quarter; 7 manufacturers in discussion
Adelaide Apothecary relocationAnnounced 18 May 2026Automated Lexington, KY facility; capacity above 2.5m prescriptions per yearOperations early 2027; Phase 1 up to US$2m
First third-party DistributeRx productJun 2026Exclusive US distribution of RECEDO® (Resilia)Live
Tariff mitigation7 Apr 2026US Section 232 tariff assessmentNo material impact expected
ANNOVERA® channel shiftFY26Move to channels with lower returnsOngoing
Climate disclosure readinessFY26–FY27Australian mandatory climate reporting (AASB S2) identified as a riskMandatory regime phase-in (see Section 20)

Medium-term targets

No quantitative revenue, EBITDA or margin guidance has been issued for FY27 or beyond. The company gives qualitative outlook statements only. The only quantified operating target is the DistributeRx and Adelaide Apothecary capacity goal of more than 2.5m prescriptions a year.

Products & Services

Women's Health (US)

ProductDescription / specificationTarget customerApproval / launchPricing / commercial notes
NEXTSTELLIS®Combined oral contraceptive: drospirenone 3 mg and estetrol (E4) 14.2 mg. The only US oral contraceptive containing estetrol, a plant-derived, body-identical estrogen. Orange Book patent protection to 2043OB/GYNs, women seeking a novel-estrogen pillFDA approval Apr 2021; licensed from Mithra (2019)FY26 US net sales US$45.2m (+6%); demand cycles +15%. Added about 15 million zero-copay covered lives in FY26 via new PBM relationships, with higher rebates. Earn-out / deferred consideration payable on US distribution rights
ANNOVERA®Segesterone acetate / ethinyl estradiol vaginal system: a single ring providing one year (13 cycles) of contraceptionWomen seeking long-acting, user-controlled contraceptionLicensed via TXMD (Dec 2022); originated by Population CouncilFY26 net sales US$25.7m (-13%); TRx +2%. Persistent product returns, so the company shifted to channels with better returns profiles. FDA-required post-approval study ongoing. US$13m (A$20m) paid to Population Council in FY25
IMVEXXY®Estradiol vaginal inserts, 4 mcg and 10 mcg, for moderate-to-severe dyspareunia due to menopausePost-menopausal women, OB/GYNsLicensed via TXMD (Dec 2022)FY26 net sales US$29.3m (+8%); TRx +6%. Patents expire 2032/2033. Paragraph IV challenges from Teva (2020) and Sun Pharma (Jun 2024). Post-approval study ongoing
BIJUVA®Estradiol / progesterone capsules (1 mg/100 mg) for moderate-to-severe vasomotor symptoms of menopause in women with a uterusMenopausal women, OB/GYNsLicensed via TXMD (Dec 2022); boxed warning removed Feb 2026FY26 net sales US$15.0m (+20%); TRx +26%, the fastest-growing brand

Dermatology (US)

ProductDescriptionIndication / targetStatusNotes
gACCUTANE® (isotretinoin)Oral retinoidSevere recalcitrant nodular acneEstablishedAbout 62% category share of new prescriptions at Q4 FY26, measured against a company-defined competitor set (IQVIA NRx)
DORYX® / DORYX MPC®Delayed-release doxycycline hyclateAcne (adjunct), infectionsEstablished; Mayne trademarkLosing share amid competitor activity and branded oral-antibiotic decline
RHOFADE®Oxymetazoline HCl cream 1%Persistent facial erythema of rosaceaEstablished; Mayne trademarkUS$37.8m net revenue in FY25 (+28%). Insurance coverage loss (FY25–26); generic launched Jul 2026, so share and volume loss expected
ORACEA® authorised genericDoxycycline 40 mg modified-releaseRosacea (papulopustular)Authorised genericCompetitive generic launches eroded FY25–26 revenue
TWYNEO®Tretinoin 0.1% / benzoyl peroxide 3% cream (NDA 214902)Acne vulgaris, ages 9 and overUS rights acquired Apr 2025; launched 1H FY26Expected loss of some insurance coverage in FY27. The FY26 Annual Report letter describes it as "tretinoin and ivermectin"; the FY25 Directors' Report and NDA description state tretinoin/benzoyl peroxide, which is taken as correct
EPSOLAY®Benzoyl peroxide cream (microencapsulated) (NDA 214510)Inflammatory lesions of rosacea, adultsUS rights acquired Apr 2025; launched 1H FY26US$16m combined consideration for TWYNEO®/EPSOLAY®
FABIOR®Tazarotene foamAcneEstablished; Mayne trademarkDetailed sales n/d
SORILUX®Calcipotriene foamPlaque psoriasisEstablished; Mayne trademarkDetailed sales n/d
LEXETTE®Halobetasol propionate foamPlaque psoriasisEstablished; Mayne trademarkDetailed sales n/d
Branded Retin-A® (tretinoin) creamTopical retinoidAcneLaunched 1H FY25Detailed sales n/d

Channel platforms (US)

PlatformDescriptionLaunchMetrics
Adelaide ApothecaryLicensed specialty mail-order pharmacy; fulfilment arm of DistributeRx. Relocating to an automated Lexington, Kentucky facility about 4 times its current footprint, with capacity over 2 phases exceeding 2.5m prescriptions per year (about 7 times current)Existing (EBITDA breakeven FY25); new facility expected early 2027Up to US$2m capex for Phase 1
DistributeRxDirect-to-patient prescription channel: digital workflows, transparent cash-pay pricing and pharmacy fulfilment. Also offers manufacturer services (co-pay optimisation, fulfilment, direct-to-pharmacy contracting)Mar 2026First full quarter (Q4 FY26): 62k TRx (+63% vs pcp) and 42k NRx (+104%); 5,042 unique prescribers. At 30 Jun 2026, in discussions with 7 manufacturers covering about 13 products (11 dermatology, 2 non-dermatology). President: Daniel Moore
RECEDO® (third-party)Topical silicone gel for scar management (Resilia Pharmaceuticals); exclusive US distribution via DistributeRxJun 2026First third-party product on the platform

International

Product / serviceDescriptionMarketNotes
KAPANOL® / KADIAN®Modified-release morphine sulfate capsules (Mayne proprietary pellet technology)Australia (KAPANOL®); Canada and export (KADIAN®)Expanded Canadian distribution agreement (FY25). KAPANOL® 200 mg launched FY24
Oxycodone productsGeneric opioid analgesicsAustraliaCited as a strong domestic seller in FY25
UROREC®SilodosinAustralia (benign prostatic hyperplasia)Cited as a strong domestic seller in FY25
NEXTSTELLIS® (Australia)Estetrol/drospirenone combined oral contraceptiveAustraliaPBS listing from 1 Oct 2025. FY26 demand cycles +127%, and +188% since PBS listing. About 520,000 Australian women used a comparable combined pill in 2024
CDMO servicesFormulation development and manufacture of complex oral and topical dose forms (modified release, poorly soluble compounds) at SalisburyGlobal clientsA$18m upgrade (A$4.8m Modern Manufacturing Initiative grant). DIFOT (delivered in full on time) 97.4% in FY26. Commercial discussions in Asian territories
Other generics / brandsMore than 57 products marketed globally (FY25 Annual Report)Australia and exportIndividual product sales n/d

Financial Narrative

Basis and sources:

  • FY22–FY23 figures are restated "continuing operations" (excluding Metrics and Retail Generics), as presented in later reports.

  • FY24–FY26 figures are from audited Annual Reports (FY25, FY26).

  • FY22–FY23 figures are from the FY23 AGM / FY24 results comparatives.

Income statement

Notes:

  • FY23 total NPAT of +A$117.2m includes a A$434.6m profit from discontinued operations, mainly the Metrics sale.

  • The FY26 Annual Report five-year table shows NPAT of -A$220.1m (FY22) and -A$317.4m (FY23) labelled as attributable to shareholders on a continuing basis.

  • FY22 gross profit and FY22–FY23 D&A were not disclosed on a comparable restated basis in the sources reviewed.

Per-share data (A$, post 20:1 consolidation)

Source: FY26 Annual Report remuneration report five-year table, and P&L. The FY23 A$0.54 was a capital distribution following asset sales.

Margins (%, analyst-computed)

Revenue CAGR:

  • FY22–FY26: (383.7/157.1)^(1/4) - 1 = about 25.0% a year. This reflects the FY24 step-change from the TXMD acquisition.

  • FY24–FY26: about -0.6% a year, essentially flat on a reported A$ basis.

Earnings quality: reported vs underlying, FY26

Source: FY25 and FY26 Annual Reports, reconciliation tables: FY26 statutory profitability is not operating profitability. The A$125.6m non-cash gain arises from writing down earn-out liabilities:

  • TXMD-related: about A$104.6–104.8m.

  • NEXTSTELLIS® US distribution rights: A$19.8m.

These write-downs reflect lower revenue forecasts for those products. Adjusted PBIT was -A$29.7m and adjusted PBT -A$71.4m.

Underlying EBITDA was also revised upward between the 31 Jul unaudited update (A$31.7m) and the audited release (A$34.2m). The A$2.5m change came from reclassifying retention-related share-based expense as a one-off adjustment.

Balance sheet

Notes:

  • FY22 net debt (A$317m) and FY23 net cash (A$172.6m) are company-reported (2024 AGM presentation).

  • The company reported FY24 net cash as A$107.6m. Analyst computation gives A$110.5m; the difference is definitional, likely lease treatment.

  • Interest-bearing debt is essentially the Dec 2022 convertible notes (carrying A$39.1m at Jun 2026, A$41.6m repayable at maturity if not converted) plus lease liabilities.

  • Earn-out liabilities are economically debt-like and far exceed the convertible notes. Including them, adjusted net debt at Jun 2026 is about A$228.7m.

  • Goodwill is not separately disclosed in the extracts reviewed.

Cash flow

Notes:

  • The FY26 media release uses A$34.5m as "operating cash flow from continuing operations before transaction and litigation costs". The Annual Report labels A$34.5m "adjusted".

  • FY26 investing inflow includes A$39.0m from redeeming marketable securities.

Ratios (analyst-computed)

Ratios not computed:

Net debt / EBITDA: net cash position, so not meaningful. Including earn-outs, about 6.7x underlying FY26 EBITDA.

Interest coverage: FY26 reported EBIT / other finance expense = A$77.5m / A$5.3m = 14.6x, but distorted by the earn-out gain. On underlying EBIT (negative) coverage is not meaningful.

Cash conversion cycle: not meaningful. Payables include large gross-to-net (rebate) accruals, and receivables are gross of rebates.

Commentary on trends, inflections and drivers

1. FY22–FY23: portfolio surgery.

The group sold Metrics (Oct 2022) and US Retail Generics (FY23), retired syndicated debt and returned capital. It swung from A$317m net debt (FY22) to A$172.6m net cash (FY23).

Continuing-operations P&L in this period was deeply loss-making:

  • Underlying EBITDA of -A$59.6m (FY22) and -A$95.3m (FY23).

  • Large intangible impairments: FY23 reported net loss included A$134.7m of depreciation, amortisation and impairment.

2. FY24 inflection.

Revenue more than doubled to A$388.4m with a full year of the TXMD brands. Underlying EBITDA turned positive (A$22.9m). Women's Health revenue rose 131% and Dermatology 207%, the latter on a gross-to-net reset and channel fixes. Statutory results were hit by:

  • A$82.7m of earn-out upward reassessments (higher forecasts, so higher liabilities).

  • A A$33.3m class action settlement.

3. FY25 peak of the turnaround.

  • Revenue +5% to A$408.1m; gross margin up to 60.6%; underlying EBITDA more than doubled to A$47.0m.

  • Adjusted operating cash flow of A$45.4m.

  • Supporting items: a A$13.2m US tax refund, and a roughly A$5.6m managed-care accrual true-up that flattered EBITDA.

4. FY26 setback with mix improvement.

Revenue fell 6%, driven by:

  • Foreign exchange: AUD/USD moved from 0.6529 to 0.6894 at year end; about A$1.9m EBITDA impact.

  • Dermatology erosion.

Underlying EBITDA fell 27%, driven by:

  • About A$7.1m of short-term incentives reinstated (nil in FY25).

  • Absence of the FY25 A$5.6m true-up.

  • A 2H step-up in Women's Health promotion.

  • Post-marketing study costs.

  • Cosette-related disruption.

Gross margin nevertheless expanded for a third straight year, to 64.7%. Statutory profit turned positive only through the A$125.6m earn-out gain.

5. Cash trajectory.

Cash and securities fell from A$149.3m (FY24) to A$100.4m (FY25) to A$80.0m (FY26). Earn-out payments (A$21.8m, A$39.8m, A$25.7m) and Cosette legal costs absorbed most organic cash generation. Sustained free cash flow after earn-outs has not yet been demonstrated.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Revenue (continuing)

157.1183.6388.4408.1383.7

Gross profit

—83.5218.8247.3248.1

Underlying (adjusted) EBITDA

-59.6-95.322.947.034.2

Reported EBITDA (continuing)

9.0-102.0-92.518.4141.4

Depreciation and amortisation

——68.569.363.7

Reported EBIT (continuing)

——-161.0-50.977.5

Pre-tax profit (continuing)

—-269.7-190.1-83.335.8

NPAT continuing operations

-220.1-317.4-168.6-90.131.2

NPAT total (incl. discontinued)

—117.2-174.2-93.824.5

Research, development, medical and regulatory expense

——20.217.920.7

Marketing and distribution expense

——130.7136.8139.6

Per share (AUD)

Per share (AUD)FY2022FY2023FY2024FY2025FY2026

Basic EPS (total)

-2.55-3.86-2.19-1.190.31

Diluted EPS (total)

——-2.19-1.190.21

Basic EPS (continuing)

——-2.12-1.140.39

Dividends / capital return per share

00.54000

Margin (%)

Margin (%)FY2022FY2023FY2024FY2025FY2026

Gross margin

—45.556.360.664.7

Underlying EBITDA margin

-37.9-51.95.911.58.9

Reported EBITDA margin

5.7-55.6-23.84.536.9

Reported EBIT (operating) margin

——-41.5-12.520.2

Net margin (continuing NPAT)

-140.1-172.9-43.4-22.18.1

Income Statement (FY2025–FY2026)

Bridge item (AUD Mn)FY2025FY2026

Reported EBITDA

18.4141.4

Earn-out reassessments (gain negative)

16.6-125.6

Restructuring incl. retention awards

1.67.2

Diligence, transaction and Cosette litigation (net of recoveries)

8.511.8

Convertible-note derivative fair-value change

-1.7-7.3

Women's Health supplier support

01.4

Drug-pricing / DOJ-related litigation

3.55.3

Underlying EBITDA

47.034.2

Balance Sheet

Metric (AUD Mn)FY2022FY2023FY2024FY2025FY2026

Total assets

——1,143.21,014.6909.4

Cash and equivalents

——110.159.880.0

Marketable securities

——39.240.60.0

Trade and other receivables

——193.2180.6174.6

Inventories

——74.650.655.5

Intangible assets (incl. goodwill)

——568.6545.8463.1

Interest-bearing debt, current (incl. leases)

——35.538.641.6

Interest-bearing debt, non-current (incl. leases)

——3.42.71.6

Total interest-bearing debt

——38.841.343.2

Other financial liabilities (earn-outs / deferred consideration)

——381.8409.1265.5

Trade and other payables

——244.5174.3194.0

Total liabilities

——689.0644.3518.5

Total equity

—634.4454.2370.3390.9

Total current assets

——460.6352.8339.5

Total current liabilities

——345.6261.0259.9

Working capital (current assets less current liabilities)

——115.091.879.5

Net debt (positive = net debt; debt less cash and marketable securities)

317.0-172.6-110.5-59.1-36.8

Cash Flow

Metric (AUD Mn)FY2024FY2025FY2026

Net operating cash flow (statutory, total)

-15.317.513.9

Operating cash flow, continuing (company estimate)

8.125.424.9

Adjusted operating cash flow, continuing (ex class action, tax refund, Cosette costs)

8.145.434.5

Capex: property, plant and equipment (net of grant)

8.011.12.9

Payments for intangibles and capitalised development

12.916.70.4

Free cash flow (statutory OCF less capex and intangibles)

-36.2-10.310.6

Earn-out and deferred settlement payments

21.839.825.7

Free cash flow after earn-out payments

-58.0-50.1-15.1

Dividends paid

000

Share buy-backs

10.900

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2024FY2025FY2026

ROE % (total NPAT / average equity)

-32.0-22.86.4

ROA % (total NPAT / average assets; FY24 on year-end assets)

-15.2-8.72.5

ROIC % (underlying EBIT x 0.7 / (equity + interest-bearing debt))

-6.5-3.8-4.8

Current ratio (x)

1.331.351.31

Debt / equity (x, interest-bearing only)

0.090.110.11

Debt incl. earn-outs / equity (x)

0.931.220.79

Asset turnover (x)

0.340.380.40

DSO (days, receivables / revenue x 365)

182162166

DIO (days, inventory / cost of sales x 365)

161115149

Geographic revenue (AUD Mn, segment proxy)

Geographic revenue (AUD Mn, segment proxy)FY2024FY2025FY2026

United States (Women's Health + Dermatology)

317.7332.5313.0

Australia and rest of world (International)

70.775.670.7

Total

388.4408.1383.7

Geographic share and growth (%)

Geographic share and growth (%)FY2024FY2025FY2026

US share of revenue

81.881.581.6

Ex-US share of revenue

18.218.518.4

US revenue growth (AUD)

—4.7-5.9

Ex-US revenue growth (AUD)

—6.9-6.5

Share price (AUD)

Share price (AUD)FY2021FY2022FY2023FY2024FY2025FY2026

30 June close

6.405.004.404.715.002.79

Performance to 30 Jun 2026 Details

Performance to 30 Jun 2026 (%)1-year3-year5-year

Price return

-44.2-36.6-56.4

Valuation Multiples

MultipleMayne (ex earn-outs)Mayne (incl. earn-outs)

P/E (FY26 reported NPAT A$24.5m)

about 10.4x (distorted by A$125.6m non-cash gain)

—

P/E (underlying)

not meaningful (underlying loss)

—

EV / underlying EBITDA (FY26 A$34.2m)

about 6.4x

about 14.2x

EV / Sales (FY26 A$383.7m)

about 0.57x

about 1.26x

P/B (equity A$390.9m)

about 0.65x

—

Capital Markets

ItemDetail

Credit ratings (Moody's / S&P / Fitch)

None; unrated

Convertible notes

Issued Dec 2022 to fund the TXMD licence. Carrying value A$39.1m (Jun 2026); A$41.6m repayable at maturity if not converted. Classified as current. Exact maturity date n/d in extracts reviewed. Embedded derivative fair-value gain of A$7.3m in FY26

Lease liabilities

About A$4.1m (derived: A$43.2m total less A$39.1m notes)

Bank debt

None (syndicated facility repaid post-FY23)

Contingent consideration

A$265.5m (current A$13.9m; non-current A$251.6m), mainly the TXMD earn-out / deferred consideration and NEXTSTELLIS® distribution rights

Analyst Conclusions

Management guidance

There is no numerical FY27 guidance. The qualitative priorities are:

  • Accelerate Women's Health, especially menopause.

  • Scale DistributeRx, including third-party products and the Lexington facility from early 2027.

  • Absorb RHOFADE® generic and TWYNEO® coverage headwinds.

  • Grow NEXTSTELLIS® in Australia and Salisbury exports and CDMO.

  • Pursue capital-efficient bolt-on M&A.

Consensus growth expectations: not publicly available (no major broker coverage).

Bull case

  1. Menopause re-rating is under way. BIJUVA® TRx +26% and IMVEXXY® TRx +6% in FY26, before a full year of boxed-warning removal. A low single-digit share of a US$15–25bn market leaves room to grow, and Women's Health gross margin is 79%.

  2. DistributeRx could become a capital-light second engine. The first full quarter delivered 62k TRx, 104% NRx growth and 5,042 prescribers, with seven manufacturers in the pipeline. Third-party fees would diversify away from Mayne's own maturing dermatology brands.

  3. Hidden asset value. The stock trades near 0.65x book and about 6.4x EV/underlying EBITDA. Mayne has A$80m cash and a live damages claim against a PE-backed bidder that agreed to pay A$7.40 a share, plus the Takeovers Panel and first-instance findings in its favour.

Bear case

  1. The operating trend is negative. Underlying EBITDA fell 27% in FY26 and Q4 EBITDA was only A$4.6m. Generic RHOFADE® and TWYNEO® coverage losses will hit FY27 dermatology revenue, and DistributeRx may not offset them before the Lexington site opens in 2027.

  2. Statutory profit masks deteriorating forecasts. The A$125.6m earn-out reversal shows management cut revenue expectations for the TXMD brands and NEXTSTELLIS®. A$265.5m of contingent liabilities remain, and free cash flow after earn-outs has been negative for three years.

  3. Litigation can cut both ways. A successful Cosette appeal would undermine the damages claim and could revive misleading-conduct allegations. The TXMD disputes, IMVEXXY® Paragraph IV cases and DOJ matters add cost (more than A$17m of litigation and transaction expense in FY26 before recoveries) and distraction.

Key catalysts and monitorables (next 12 months)

Catalyst / monitorableExpected timingWhy it matters
NSW Court of Appeal decision on Cosette appealAny time (reserved since Jun 2026)Determines leverage in the damages suit
Progress / settlement of damages claim vs Cosette, Avista and BurgstahlerFY27Potentially transformational cash recovery
Q1 FY27 quarterly updateAbout late Oct 2026First read on RHOFADE® generic impact and BIJUVA® trajectory
2026 AGMAbout Nov 2026 (date n/d)Board endorsement of new directors; capital-management signals
1H FY27 resultsAbout late Feb 2027EBITDA recovery test
Lexington, KY facility start-upEarly 2027DistributeRx capacity
Additional third-party DistributeRx signingsOngoingPlatform validation
IMVEXXY® Paragraph IV developmentsOngoingPatent life to 2032–2033 at risk
TXMD Delaware litigation / dispute resolutionOngoingContingent liability
Convertible note maturity / conversionWithin 12 months (classified current)About A$41.6m cash call if not converted
Funicular Funds / board-led capital-allocation actions (buy-back, M&A, strategic review)FY27Shareholder-value unlock
First mandatory climate-related financial disclosuresFY27 reportingCompliance

Analyst verdict

Mayne Pharma enters FY27 as a company whose intrinsic franchise quality has improved while its reported trajectory has worsened.

What is going right. The portfolio surgery of FY22–FY24 worked. A loss-making generics conglomerate with A$317m of net debt became a focused US branded business with a 64.7% gross margin, no bank debt and A$80m of cash. The menopause assets now have a real regulatory tailwind. NEXTSTELLIS® retains a long patent runway. DistributeRx is a credible, if early, answer to the collapse of branded-dermatology economics.

What went wrong. FY26 exposed the fragility beneath. Underlying EBITDA fell to A$34.2m and the fourth quarter almost broke even at the EBITDA line. Statutory profit was produced only by writing down earn-out liabilities, which is an admission that acquired-brand forecasts were too optimistic. Contingent consideration of A$265.5m still absorbs most of the free cash flow the business generates. The failed Cosette transaction consumed a year of management bandwidth, triggered wholesale leadership turnover and left the register with event-driven holders rather than long-only institutions.

How the equity is priced. At around A$2.5–3.2 a share, the market capitalises Mayne at roughly a third to two-fifths of the A$7.40 scheme price. That valuation sits near book value, at a mid-single-digit multiple of trough EBITDA excluding earn-outs. The equity is effectively a call option on three things:

  1. A favourable Court of Appeal outcome and meaningful damages recovery.

  2. Menopause-led Women's Health growth outrunning dermatology erosion.

  3. DistributeRx reaching third-party scale once the Lexington facility opens.

Balance of probabilities. The balance sheet gives the company time, and the damages claim supplies asymmetric upside. Operating proof points are lacking, however: positive free cash flow after earn-outs and stabilising group revenue in US-dollar terms. Until they appear, a cautious, catalyst-driven stance is warranted rather than a fundamental re-rating thesis.

Bottom line: speculative value with binary legal catalysts. Two signals to watch most closely are the reserved appeal judgment and the 1H FY27 EBITDA print.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior roles / backgroundEducation / age

Aaron Gray

Chief Executive Officer

CEO since 20 Feb 2026; CFO Aug 2022–Feb 2026; joined Jul 2022

Led the financial turnaround and margin program; central to the Cosette process and DistributeRx development

Age n/d

Griffin D. Buchanan

Chief Financial Officer

From 1 Aug 2026

Senior finance executive with global medtech and healthcare (women's health) experience

—

Daniel Moore

President, DistributeRx

2,026

Formerly General Manager, Dermatology; more than 20 years in healthcare commercial roles

—

Laura Loftus

Company Secretary

Since Mar 2020; with Mayne since May 2014

Former solicitor, DLA Piper

BCom, LLB (Hons), Monash; GAICD

Dr Tom Duthy

Investor Relations

Current

IR contact

—

Directors' Remuneration

ExecutiveSalarySTITerminationOther benefitsSuperDeferred STILTI / RSUsTotal FY26Total FY25

Aaron Gray (CEO, formerly CFO)

1,050,781265,904029,30112,30614,077905,8752,279,2451,218,983

Shawn O'Brien (former CEO)

907,359345,656663,423245,88217,73911,679527,5982,719,3372,129,807

Board of Directors

DirectorRoleAppointedAgeBackgroundCommitteesFY26 fees (AUD)

Prof Bruce Robinson AC

Independent Chair (from 14 Jan 2026)

26 Aug 2014

70

Endocrinologist; former Dean, Sydney Medical School; NED of Cochlear, Lorica, QBiotics; Chair of NHMRC

Audit & Risk (member); Nomination (Chair)

222,619

Ann Custin

Independent NED

23 Mar 2022

66

Former Board Director and CFO, Siemens Medical Solutions; former CEO of Draeger Medical Systems (USA); NED of Establishment Labs

Audit & Risk (Chair); Remuneration & People (Chair); Nomination

208,657

David Petrie

NED

1 Sep 2022

60

Principal, Stratford Advisory; 23 years at Merrill Lynch / BofA (Head of IB Melbourne)

Audit & Risk; Remuneration & People; Nomination

194,440

Meghan Rivera

Independent NED

26 Jun 2026

47

VP & Global Commercial Lead, ViiV Healthcare; former US Market President, Organon; former SVP Women's Health, AMAG

Remuneration & People; Nomination

nil in FY26

Jacob Ma-Weaver

NED (shareholder nominee profile)

14 Aug 2026

39

Founder and Managing Member, Cable Car Capital (general partner of Funicular Funds, 9.90% holder); former board member of ARCA biopharma; Amici Capital, Dodge & Cox, McKinsey

——

Major Shareholders

HolderShares%

Funicular Funds LP (Cable Car Capital)

8,045,3499.90

Bruce Mathieson

5,292,0666.51

Rubric Capital Management LP

4,356,4265.36

Trium Capital LLP

4,086,2435.02

Citicorp Nominees

8,310,35210.23

BNP Paribas Nominees (IB Au Noms Retail)

7,932,1429.76

HSBC Custody Nominees A/C 2

5,409,3046.66

BMG B J MYX Pty Ltd (Mathieson-related)

5,183,4776.38

HSBC Custody Nominees (GSCO Customers)

4,457,1595.49

BNP Paribas Nominees (Cowen and Co LLC)

2,406,6012.96

HSBC Custody Nominees

2,298,0862.83

Warbont Nominees

2,014,0932.48

BNP Paribas Noms

1,496,2451.84

Dr Kenney Wan

1,355,3911.67

Competitive Landscape

Competitors by Segment

SegmentCompetitorCompeting products / positioning

Women's Health: contraception

Organon & Co.

Broad women's-health franchise (contraceptives, Nexplanon implant)

Women's Health: contraception

AbbVie

Lo Loestrin Fe (branded combined oral contraceptive)

Women's Health: contraception

Bayer

Yaz/Yasmin family (drospirenone COCs), IUS products

Women's Health: contraception

Exeltis (Insud Pharma), incl. ex-Agile Therapeutics

Slynd (progestin-only pill), Twirla patch

Women's Health: contraception

Generic COC manufacturers (Lupin, Glenmark, Xiromed, others)

Low-cost generic pills, the main price competition

Women's Health: menopause

Pfizer

Premarin / Prempro / Premarin Vaginal Cream

Women's Health: menopause

Astellas

Veozah (fezolinetant), a non-hormonal VMS treatment

Women's Health: menopause

Bayer

Non-hormonal elinzanetant (VMS)

Women's Health: menopause / sexual health

Cosette Pharmaceuticals

Intrarosa, Vyleesi, Clomid; now a direct adversary in litigation

Women's Health: vaginal estrogen generics

Teva, Sun Pharma (ANDA filers vs IMVEXXY®)

Potential generic entry

Dermatology

Galderma

Market leader in aesthetics and dermatology (rosacea and acne brands)

Dermatology

Bausch Health (Ortho Dermatologics)

Acne and psoriasis topicals

Dermatology

Sun Pharma (US specialty derm)

Branded and generic dermatology

Dermatology

Journey Medical

Small-cap US derm (incl. a rosacea minocycline product)

Dermatology

Almirall, Verrica, generic topical makers

Niche brands and generics

Direct-to-patient channel

GoodRx, Mark Cuban Cost Plus Drugs, BlinkRx, Amazon Pharmacy, manufacturer DTC portals

Cash-pay and digital pharmacy

International (Australia)

Viatris, Sandoz, Arrotex, Apotex; CDMOs such as Catalent and Lonza

Generics and contract manufacturing

Peer Comparison FY2026

MetricMayne Pharma (FY26)Organon (CY2024)Galderma (CY2024)Journey Medical (CY2024)

Revenue

A$383.7m (about US$260m)

about US$6.4bn

about US$4.4bn

about US$56m

Revenue growth

-6% (A$); about flat in US$

about +1%

about +9%

about -29%

Gross margin

64.7%———

R&D intensity

5.4%———

Profitability

Underlying EBITDA margin 8.9%

———

Recent Developments

--

Company Snapshot

470

Employees

2005

Founded

Salisbury South, Australia

Headquarters

SWOT Analysis

Strengths

  • Margin expansion. Group gross margin rose for three consecutive years: 56.3% (FY24), 60.6% (FY25), 64.7% (FY26) (FY26 Annual Report).
  • High-quality Women's Health franchise. Segment gross margin was 79% and direct contribution A$57.9m in FY26.
  • Long IP runway on the lead brand. NEXTSTELLIS® has Orange Book patents to 2043.
  • Menopause momentum. BIJUVA® TRx rose 26% and net sales 20% in FY26; IMVEXXY® TRx rose 6% (FY26 media release).
  • Proprietary channel. DistributeRx generated 62k TRx (+63%) and 42k NRx (+104%) in its first full quarter, from 5,042 prescribers (FY26 media release).
  • Clean interest-bearing balance sheet. Cash of A$80.0m against A$43.2m of interest-bearing debt at 30 Jun 2026.
  • Legal track record against Cosette. Mayne won the first-instance judgment (Oct 2025) and the Takeovers Panel declaration (Nov 2025), and recovered A$14.4m in costs (Jun 2026).

Weaknesses

  • Underlying EBITDA fell 27% to A$34.2m in FY26. Q4 FY26 EBITDA was only A$4.6m (-76%).
  • Dermatology revenue in multi-year decline: A$174.9m (FY24), A$154.1m (FY25), A$138.7m (FY26).
  • Contingent consideration burden. Earn-out and deferred liabilities of A$265.5m, with A$34.2m a year of non-cash discount unwind and A$25.7m of cash payments in FY26.
  • Weak cash generation after obligations. Free cash flow after earn-outs was -A$15.1m (FY26), -A$50.1m (FY25) and -A$58.0m (FY24).
  • Statutory profit is non-operating. FY26 NPAT relied on a A$125.6m non-cash earn-out write-down that signals lower product forecasts. Adjusted PBT was -A$71.4m.
  • ANNOVERA® weakness. Net sales fell 13% to US$25.7m on persistent returns.
  • Governance churn. The CEO, CFO, Chair and four directors changed within about eight months (Jan–Aug 2026). Only 3 of 5 directors are independent.

Opportunities

  • HRT boxed-warning removal. This reopens a menopause market forecast at US$15–25bn by 2030, where Mayne holds only a low single-digit share.
  • Third-party DistributeRx revenue. Seven manufacturers and about 13 products were in discussion at 30 Jun 2026; Resilia was the first signed.
  • Capacity scale-up. The Lexington facility lifts capacity about seven-fold, to more than 2.5m prescriptions a year, from early 2027.
  • NEXTSTELLIS® in Australia. Demand cycles are up 188% since PBS listing, against a pool of about 520k comparable-pill users.
  • Damages claim. The suit against Cosette, Avista and Burgstahler (filed Feb 2026) is for an unquantified "substantial" amount. The gap between A$7.40 scheme value and about A$2.5–3.2 trading prices frames the potential quantum.
  • Salisbury exports and CDMO. Commercial discussions with Asian territories are under way and DIFOT has reached 97.4%.
  • Accretive bolt-on acquisitions, given A$80m cash and a stated M&A appetite.

Threats

  • Generic entry and coverage loss. Generic RHOFADE® launched Jul 2026, and management expects TWYNEO® insurance coverage loss in FY27.
  • IMVEXXY® Paragraph IV challenges from Teva and Sun Pharma against patents expiring 2032–2033.
  • Adverse appeal outcome. The Court of Appeal decision on Cosette's appeal is reserved (heard 2–3 Jun 2026).
  • TXMD litigation in Delaware: claims and counterclaims, with the working-capital dispute in a dispute-resolution process.
  • FX translation drag. AUD/USD moved from 0.6529 to 0.6894 over FY26; about 82% of revenue is in US$.
  • US drug-pricing and healthcare policy. Ongoing DOJ / drug-pricing investigation costs were A$5.3m in FY26.
  • PBM rebate intensification. It offset some NEXTSTELLIS® volume gains in FY26 net sales.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
8 Apr 2025TXMD files suit against Mayne (D. Del.): breach of contract, implied covenant, fraudulent inducement, unjust enrichment over the licence / transaction agreement and net working capitalLitigation overhang on a key licensor relationship
22 Apr 2025TWYNEO® / EPSOLAY® acquisition (US$16m) and earnings updateDermatology mix upgrade; the earnings update was later cited by Cosette
15 May 2025Court approves scheme booklet dispatchScheme progresses
17 May 2025Cosette alleges a Material Adverse ChangeStart of the takeover dispute
30 May 2025Mayne countersues TXMD (D. Del.) for breach and fraudulent inducementTwo-way litigation
4 Jun 2025Cosette purports to terminate the SIDShares fall; Mayne sues in NSW Supreme Court
18 Jun 2025Shareholders approve the scheme (99.06% of votes; 89.64% by headcount)Strong shareholder mandate
29 Aug 2025FY25 results: revenue A$408.1m (+5%); underlying EBITDA A$47.0m (+105%)Turnaround peak
29 Sep 2025NEXTSTELLIS® PBS listing approved (effective 1 Oct)Australian growth driver
15 Oct 2025NSW Supreme Court (Black J) rules Cosette's termination invalid, finds no MAC, and dismisses Cosette's cross-claims with costsMajor legal win
10 Nov 2025Cosette files notice of intention to appealProlongs the dispute
14 Nov 2025Takeovers Panel interim orders extend the scheme End Date to 24 Nov 2025Keeps the deal alive
19 Nov 2025Panel declares unacceptable circumstances: the market was uninformed of Cosette's changed Salisbury intentions (24 Jun–8 Sep 2025). Cosette ordered to accept FIRB conditions consistent with its original intentionsRegulatory finding against the bidder
21 Nov 2025Treasurer Jim Chalmers objects to the scheme (national interest); trading halt. Shares fall from about A$5.79 to the A$4.45–3.24 rangeDeal effectively dead
3 Dec 2025Mayne serves notice of intention to terminate for Cosette's alleged wilful breaches (FIRB engagement, financing)Sets up damages claim
9 / 11 Dec 2025Cosette (9 Dec) and Mayne (11 Dec) serve termination notices; no break fee payable by MayneFormal end of the scheme
Dec 2025Retention awards granted; Salisbury upgrade inauguratedTalent retention; capacity
18 Dec 2025Former CEO O'Brien sells 129,736 shares at about A$3.09Insider selling
14 Jan 2026Chair Condella retires; Blake and Lockwood to step down; Robinson becomes ChairGovernance reset
15 Jan 2026Cosette lodges notice of appeal on two grounds (FY25 EBITDA / misleading conduct findings; MAC on Q3 FY25 sales)Appeal live
29 Jan 2026Delayed 2025 AGM held in MelbourneGovernance
Feb 2026FDA removes boxed warning from BIJUVA®Menopause tailwind
18 Feb 2026Damages proceedings filed against Cosette, Cosette Holdings, Avista and David BurgstahlerPotential material recovery
20–23 Feb 20261H FY26 results (revenue steady, gross margin +3.9pp, EBITDA -8%). CEO O'Brien steps down; Aaron Gray appointed CEOLeadership transition
Mar 2026DistributeRx launchedNew growth platform
7 Apr 2026US Section 232 tariffs: no material impact expectedRisk removed
7 May 20263Q FY26 investor presentationOperational update
18 May 2026Adelaide Apothecary expansion to Lexington, KYCapacity about 7 times current
22 May 2026Court awards A$13.27m in legal costs against CosetteCash recovery
1 Jun 2026Resilia RECEDO® DistributeRx partnershipThird-party validation
2–3 Jun 2026NSW Court of Appeal hears Cosette appeal; decision reservedPending catalyst
4–5 Jun 2026Jefferies Healthcare Conference presentation; A$14.4m received from Cosette (costs plus interest). Shares from about A$2.21Cash inflow
Jun 2026Funicular Funds lifts its stake from 6.30% to 9.90%Activist-style accumulation
26 Jun 2026Meghan Rivera appointed NEDUS commercial expertise
Jul 2026Generic RHOFADE® launchedDermatology revenue headwind
17 Jul 2026Griffin Buchanan appointed CFO (from 1 Aug)Management completed
31 Jul 2026Unaudited Q4: revenue A$86.5m (-22%); Q4 underlying EBITDA A$4.6m (-76%)Weak quarter; shares nonetheless rallied
3–5 Aug 2026Bioshares Summit presentation; Jacob Ma-Weaver appointment announced (effective 14 Aug)Shareholder representation on board
27 Aug 2026FY26 results and Annual Report–
Sep–Oct 2026No further material announcements verified. Court of Appeal decision still reserved as of the latest verified disclosureMonitor

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue (continuing) rose from AUD 157.1 Mn in FY2022 to AUD 383.7 Mn in FY2026.
Mayne Pharma Group Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2022FY2023FY2024FY2025FY2026
Revenue (continuing)157.1183.6388.4408.1383.7
Gross profit—83.5218.8247.3248.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Mayne Pharma FY26 Appendix 4E and Annual Report, 27 Aug 2026 (ASX)
  2. Mayne Pharma FY26 Results Media Release, 27 Aug 2026 (ASX)
  3. Mayne Pharma Q4 / FY26 Unaudited Results, 31 Jul 2026 (ASX)
  4. Mayne Pharma FY26 Results Call (transcript summary), 26–27 Aug 2026
  5. Mayne Pharma FY25 Annual Report, 14 Oct 2025 (ASX)
  6. Mayne Pharma FY25 Results Release, 29 Aug 2025 (ASX)
  7. Mayne Pharma FY24 Appendix 4E and Results Release, 23 Aug 2024 (ASX)
  8. Mayne Pharma 1H FY24 Results, 26 Feb 2024 (ASX)
  9. 2023 AGM presentation (30 Nov 2023), 2024 AGM presentation (21 Nov 2024), 2025 AGM address and presentation (29 Jan 2026)
  10. ASX announcements
  11. Scheme meeting results (18 Jun 2025)
  12. Notice of hearing (21 Oct 2025)
  13. Scheme update (10 Nov 2025)
  14. Board changes (14 Jan 2026)
  15. Notice of appeal (15 Jan 2026)
  16. Costs award (22 May 2026)
  17. Costs receipt (5 Jun 2026)
  18. Takeovers Panel media releases TP25/093 and TP25/095, and reasons 2025 ATP 35
  19. Cosette Pharmaceuticals press release, 11 Dec 2025
  20. TherapeuticsMD Forms 10-Q (2025) and 10-K/A (FY2025), SEC EDGAR
  21. Market data: Market Index (marketindex.com.au), InvestSMART, Simply Wall St, GuruFocus
  22. Press: Capital Brief, Business News Australia, InDaily SA, Pharmacy Daily, American Pharmaceutical Review, Herbert Smith Freehills Kramer insights

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.